NCT06480461View on ClinicalTrials.gov

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2031

Conditions
Parkinson's Disease
Interventions
DRUG

VGN-R09b

This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.

All Listed Sponsors
lead

Shanghai Vitalgen BioPharma Co., Ltd.

INDUSTRY

NCT06480461 - A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter